U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H17F6N7O
Molecular Weight 473.375
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ENASIDENIB

SMILES

CC(C)(O)CNC1=NC(NC2=CC(=NC=C2)C(F)(F)F)=NC(=N1)C3=NC(=CC=C3)C(F)(F)F

InChI

InChIKey=DYLUUSLLRIQKOE-UHFFFAOYSA-N
InChI=1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32)

HIDE SMILES / InChI

Molecular Formula C19H17F6N7O
Molecular Weight 473.375
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Enasidenib, aslo known as AG-221 and CC-90007, is a potent and selective IDH2 inhibitor with potential anticancer activity (IDH2 = Isocitrate dehydrogenase 2). The mutations of IDH2 present in certain cancer cells result in a new ability of the enzyme to catalyze the NAPH-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG). The production of 2HG is believed to contribute to the formation and progression of cancer. The inhibition of mutant IDH2 and its neoactivity is therefore a potential therapeutic treatment for cancer. Enasidenib is an orally available, selective, potent inhibitor of the mutated IDH2 protein, making it a highly targeted investigational medicine for the potential treatment of patients with cancers that harbor an IDH2 mutation. Enasidenib has received orphan drug and fast track designations from the U.S. FDA. Enasidenib mesylate is in phase II clinical trials for Solid tumours and phase III clinical trials for the treatment of acute myeloid leukaemia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
12.0 nM [IC50]
Conditions
PubMed

PubMed

TitleDatePubMed
[Progress in molecularly targeted therapies for acute myeloid leukemia].
2015 Feb
IDH2 inhibition in AML: Finally progress?
2015 Jun-Sep
The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.
2016
Patents

Sample Use Guides

In Vivo Use Guide
Continuous 28-day cycles of Enasidenib (AG 221) 100 mg orally (PO) once a day (QD) for 28 days, plus BSC.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Oct 21 21:27:48 UTC 2019
Edited
by admin
on Mon Oct 21 21:27:48 UTC 2019
Record UNII
3T1SS4E7AG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ENASIDENIB
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
AG-221
Code English
2-METHYL-1-(4-(6-(TRIFLUOROMETHYL)PYRIDIN-2-YL)-6-(2-(TRIFLUOROMETHYL)PYRIDIN-4-YLAMINO)-1,3,5-TRIAZIN-2-YLAMINO)PROPAN-2-OL
Systematic Name English
ENASIDENIB [USAN]
Common Name English
2-PROPANOL, 2-METHYL-1-((4-(6-(TRIFLUOROMETHYL)-2-PYRIDINYL)-6-((2-(TRIFLUOROMETHYL)-4-PYRIDINYL)AMINO)-1,3,5-TRIAZIN-2-YL)AMINO)-
Systematic Name English
ENASIDENIB [WHO-DD]
Common Name English
AG 221 [WHO-DD]
Common Name English
ENASIDENIB [INN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 434514
Created by admin on Mon Oct 21 21:27:48 UTC 2019 , Edited by admin on Mon Oct 21 21:27:48 UTC 2019
NDF-RT N0000193615
Created by admin on Mon Oct 21 21:27:48 UTC 2019 , Edited by admin on Mon Oct 21 21:27:48 UTC 2019
NCI_THESAURUS C137826
Created by admin on Mon Oct 21 21:27:48 UTC 2019 , Edited by admin on Mon Oct 21 21:27:48 UTC 2019
WHO-ATC L01XX59
Created by admin on Mon Oct 21 21:27:48 UTC 2019 , Edited by admin on Mon Oct 21 21:27:48 UTC 2019
Code System Code Type Description
CAS
1446502-11-9
Created by admin on Mon Oct 21 21:27:48 UTC 2019 , Edited by admin on Mon Oct 21 21:27:48 UTC 2019
PRIMARY
PUBCHEM
89683805
Created by admin on Mon Oct 21 21:27:48 UTC 2019 , Edited by admin on Mon Oct 21 21:27:48 UTC 2019
PRIMARY
NCI_THESAURUS
C111573
Created by admin on Mon Oct 21 21:27:48 UTC 2019 , Edited by admin on Mon Oct 21 21:27:48 UTC 2019
PRIMARY
CAS
1802003-09-3
Created by admin on Mon Oct 21 21:27:48 UTC 2019 , Edited by admin on Mon Oct 21 21:27:48 UTC 2019
NO STRUCTURE GIVEN
INN
10162
Created by admin on Mon Oct 21 21:27:48 UTC 2019 , Edited by admin on Mon Oct 21 21:27:48 UTC 2019
PRIMARY
RXCUI
1940332
Created by admin on Mon Oct 21 21:27:48 UTC 2019 , Edited by admin on Mon Oct 21 21:27:48 UTC 2019
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
EXCRETED UNCHANGED
URINE
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
CUMULATIVE EXCRETION
FECAL
EXCRETED UNCHANGED
FECAL
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
CUMULATIVE EXCRETION
URINE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> NON-SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> NON-SUBSTRATE
Related Record Type Details
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
PERMEABILITY CHEMICAL MEMBRANE TYPE

Tmax PHARMACOKINETIC